Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 4/20 | 0.79 |
| ▸ | PLK1 | P53350 | 2/20 | 0.79 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.71 |
| ▸ | RAF1 | P04049 | 7/20 | 0.68 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.65 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.65 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.65 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.65 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.65 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KIF15 | Q9NS87 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | ARAF | P10398 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395085 | 1.00 | PLK4 (0.79) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL5771999 | 0.90 | PLK4 (0.65) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL5772003 | 0.90 | PLK4 (0.65) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL7979353 | 0.89 | PLK4 (1.00) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL7979350 | 0.89 | PLK4 (1.00) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL1395409 | 0.86 | LRRK2 (0.76) | PLK4PLK1RAF1LRRK2PSEN1 | |
| SCHEMBL5774039 | 0.86 | MAP1LC3B (0.88) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL5774043 | 0.86 | MAP1LC3B (0.88) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL3754416 | 0.86 | MAP1LC3B (0.88) | PLK4PLK1MAP1LC3BRAF1LRRK2 | |
| SCHEMBL1395411 | 0.86 | LRRK2 (0.76) | PLK4PLK1RAF1LRRK2PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| WO-2014172616-A2 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | PLK4 3367/4885PLK1 3234/4885MAP1LC3B 82/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | PLK4 2631/4885PLK1 1598/4885MAP1LC3B 54/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | PLK4 3482/4885PLK1 2516/4885MAP1LC3B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.